Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
ISTH Bangkok Workshop Program
Share |

Workshop Home | Registration (coming soon) | Accommodations

Program

Course Chairmen: Pantep Angchiasuksiri, MD and Ponlapat Rojnuckarin, MD, PhD

 

Target Audience:

  • Trainees in hemostasis, hematology, transfusion medicine, vascular medicine, or intensive care medicine
  • A Ph.D. wishing to acquire clinical and basic knowledge in the field
  • A senior hematologist looking for an update

Objectives:

  1. Obtain an understanding of the latest developments in coagulation and bleeding disorder management
  2. Learn to identify, diagnose and have knowledge of the latest treatment for patients with risk of thrombosis
  3. Have the opportunity to network with leading experts in the field of thrombosis and hemostasis, benefiting from the small training size (250 maximum participants)


Detailed Program

November 3

16:00-19:00 Registration 

 

November 4

07:00 Registration opens
08:30-12:45 Pre-workshop supported symposia


Subtopic: Introduction

Time Event Speaker
INTRODUCTION AND GLOBAL IMPACT/EPIDEMIOLOGY:
13:30 - 14:00

Venous thrombosis in Asia

Participants in this session will gain an understanding of the current incidence and burden of VTE in Asia;  how to increase awareness of VTE in Asian populations and learn about World Thrombosis Day activities.

Pantep Angchaisuksiri (Thailand)
14:00 - 14:30 Bleeding disorders in Asia Ponlapat Rojnuckarin (Thailand)
14:30 - 15:30

Current concepts of the coagulation system with emphasis on hemostasis

In this presentation participants will review traditional and novel concepts of the coagulation ‘cascade’; gain an understanding of how single coagulation deficiency states may manifest clinically and review the pathophysiology of some complex coagulopathies that manifest as bleeding.

Nigel Key (USA)
15:30 - 16:00 Coffee break & networking
OVERVIEW OF HEMOSTATIC ASSAYS AND THEIR CLINICAL USES
16:00 - 16:30

Coagulation assays

In this presentation participants will review the basic principles of traditional coagulation assays; review the basic principles of global assays of coagulation and gain an understanding of the strengths and limitations of commonly used assays.

Nigel Key (USA)
16:30 - 17:00

Platelet function assays

This presentation will provide basic knowledge on various platelet function tests, ranging from the conventional adhesion and aggregation test, to the more recently-developed instruments simulating in vivo blood flow. The participants will gain a deeper understanding of platelet physiology as well as various techniques to elucidate numerous facets of platelet functions.

Yukio Ozaki (Japan)
17:00 - 17:30

Fibrinolytic assays

Following this presentation, participants will be able to explain the assay method to detect fibrinolytic activity and to evaluate the obtained values.

Tetsumei Urano (Japan)

WORK-UP OF A PATIENT:
17:30 - 18:00

How to approach a patient with thrombosis

Participants in this session will learn to be cognizant of key medical history taking and physical exam details that enable accurate diagnosis, appropriate treatment and optimal counseling of the patient with VTE; how to recognize the pitfalls of diagnostic tests (venous Doppler ultrasound, nuclear-medicine lung ventilation-perfusion scan, computer-tomography venography) and how to make evidence based decisions on length of anticoagulation treatment in patients with VTE.

Stephan Moll (USA)
18:00 - 18:30

How to approach a patient with bleeding

In this presentation participants will review bleeding assessment tools used in the clinical evaluation of a possible bleeding disorder patient; review the major categories of disorders that present with mild to moderate bleeding and gain an understanding of the term ‘bleeding of uncertain cause’ and the clinical management of these patients.

Nigel Key (USA)
18:30 - 21:00 Welcome dinner & networking

November 5
Subtopic: Congenital bleeding disorders

Time Event Speaker
VON WILLEBRAND DISEASE
8:30 - 9:15

The diagnosis of VWD: Interpreting laboratory tests for a complex genetic disorder

Participants will learn about the range of phenotypic tests available to assist in the diagnosis of VWD. Participants will be provided with guidance on the application and interpretation of these tests. Finally, the integration of genetic testing in the diagnosis of VWD will be discussed.  

David Lillicrap (Canada)
9:15 - 10:00

Management of VWD

Participants will learn about the different von Willebrand disease scenarios that require treatment both during active bleeding and prophylaxis. After the lecture they will be familiar with the two main treatments of desmopressin and FVIII/VWF concentrates and understand their appropriate uses. They will also learn about the VWD within subtype heterogeneity and how this influences treatment. 

Michael Makris (UK)
10:00 - 10:30 Coffee break & networking
HEMOPHILIA:
10:30 - 11:15

Laboratory testing for the diagnosis and monitoring of therapy in hemophilia

In this presentation, the participants will be provided with guidance on the types of laboratory testing that can be used to optimize diagnostic approaches and treatment outcomes in hemophilia. Recommendations on the use and interpretation of genetic testing will also be discussed.

David Lillicrap (Canada)
11:15 - 12:00 Management and complications Flora Peyvandi (Italy)
12:00 - 13:30 Lunch &sponsored symposium
HEMOPHILIA:
13:30 - 14:15

Future treatment of hemophilia: Spoiled for choice

The participants of this session will be provided with information relating to the range and diversity of future therapies for hemophilia. New engineered protein replacement therapies will be discussed as well as the growing number of non-factor replacement treatments. Lastly, an update will be provided relating to the advances in gene therapy for hemophilia.    

David Lillicrap (Canada)
14:15 - 15:00

Management of hemophilia under limited resources

Participants will learn about the advantage of replacement at an early bleeding episode; affordable options for low-dose prophylaxis and the initiation of immune tolerance as soon as possible.

Ampaiwan Chuansamrit (Thailand)
15:00 - 15:30 Coffee break & networking
15:30 - 16:00 Rare bleeding disorders Flora Peyvandi (Italy)
16:00 - 16:30

Congenital platelet disorders

In this lecture participants will learn about the classification of inherited qualitative and quantitative platelet disorders. For the qualitative defects the relative role of tranexamic acid, rFVIIa and platelet transfusions together with their complications will be addressed. They will understand the impact on treatment of the expanding list genes causing inherited thrombocytopenias and how they influence the phenotype.

Michael Makris (UK)
16:30 - 17:00 Thrombotic thrombocytopenia purpura  Flora Peyvandi (Italy)
17:00 - 18:00 Meet the Expert session  
 

November 6
Subtopic: Acquired hemostatic disorders

Time Event Speaker
8:30 - 9:00

Acquired hemophilia

After this presentation, participants will understand the pathogenesis of FVIII inhibitor development; be acquainted with the manifestation of acquired hemophilia and laboratory for the diagnosis and treat the bleeding manifestation properly.

Theera Ruchutrakool (Thailand)
9:00 - 9:30

Hemolytic uremic syndrome

Participants in this session will gain an understanding of the pathogenesis of hemolytic uremic syndrome; understand the differential diagnosis methods of Shiga toxin-producing hemolytic uremic syndrome (STEC-HUS), atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP) and gain an understanding of the current guidelines to manage HUS and aHUS.

Doyeun Oh (Korea)
9:30 - 10:00

Disseminated intravascular coagulation

Participants will learn about the recent progress in diagnosis and treatment of DIC, especially about the scoring system, anticoagulant therapy, and new drug clinical trials.

Yu Hu (China)
10:00 - 10:30 Coffee break & networking
10:30 - 11:00

Thrombosis in bleeding disorders

Whilst patients with inherited bleeding disorders have a reduced thrombotic risk overall this is increasingly recognized as an issue. In this lecture, participants will learn about the baseline and treatment associated thrombotic risks, together with the evidence as to whether certain concentrates are more prothrombotic than others. Participants will also learn about the treatment of acute thrombosis, surgical thromboprophylaxis and management of atrial fibrillation in inherited bleeding disorder patients.

Michael Makris (UK)
11:00 - 11:30 Heparin-induced thrombocytopenia Christopher Ward (Australia)
11:30 - 12:00

Hemostasis in liver disease and management

Liver disease is often accompanied with severe blood clotting problem, how to diagnose and manage the issues are very important in clinical practice. Through the lecture, participants will learn to master the diagnosis and differential diagnosis skills, and learn about the new progress in comprehensive treatment.

Yu Hu (China)
12:00 - 13:30 Lunch & sponsored symposium
13:30 - 14:00 Hematologist approach to management of postpartum hemorrhage Claire McLintock (New Zealand)
14:00 - 14:30

Laboratory tests for transfusion on massive bleeding

Upon completion of this course, participants should be able to discuss the pathophysiology of high-risk disorders for massive bleeding; interpret the laboratory test values to diagnose and evaluate bleeding; discuss the management strategies for patients with massive bleeding risks and describe hemostatic agents to prevent and reduce the bleed during and after invasive procedures.

Satoshi Fujii (Japan)
14:30 - 15:00

Fibrinolysis related hemostatic- and thrombotic- disorders

Following this presentation participants will be able to explain the physiological role of fibrinolytic system; explain the risk factors to suppress fibrinolytic activities and to induce thrombosis and explain the mechanism to induce bleeding tendency due to malfunction of regulatory system of fibrinolysis.

Tetsumei Urano (Japan)
15:00 - 15:30 Coffee break & networking
REGIONAL SUBJECTS:
15:30 - 16:00 Hypercoagulability in thalassemia Pichika Chantrathammachart (Thailand)
16:00 - 16:30 Snake venom and coagulopathy Ponlapat Rojnuckarin (Thailand)
16:30 - 17:00

Hemostatic derangement in Dengue infection

In this lecutre, participants will learn to update the current WHO revised classification of Dengue fever; to understand the hematologic and hemostatic changes in dengue infection; to discuss the clinical and laboratory predictor in patients with severe dengue, the role of thromboelastometry to monitor hemostatic defects in patients with dengue infection and to review current treatment modalities of bleeding in dengue patients.

Darintr Sosothikul (Thailand)
17:00 - 17:30

Case study/interactive presentation – patient with bleeding history

Participants will be invited to prepare case presentations for the audience and a discussion of the presentations will be moderated by Dr. Nigel Key.

Moderator: Nigel Key (USA)
17:30 - 18:30 Meet the Expert session
:

November 7
Subtopic: Women's Issues in Hemostasis/Venous Thrombosis

Time Event Speaker
WOMEN'S ISSUES IN HEMOSTASIS
8:30 - 9:00 Diagnosis of VTE in pregnancy Claire McLintock (New Zealand)
9:00 - 9:30

Management of VTE in pregnancy

Following this lecture, the participants should be able to decide which pregnant patient with a thrombophilia or a history of VTE should receive VTE prophylaxis; order the appropriate imaging tests for a pregnant patient presenting with symptoms and findings suggestive of DVT or PE; treat a pregnant patient with VTE with anticoagulation and manage the peri-delivery period and advise a patient which anticoagulants are safe to use postpartum while breastfeeding.

Stephan Moll (USA)
9:30 - 10:00 Bleeding in women/pregnancy Claire McLintock (New Zealand)
10:00 - 10:30 Coffee break & networking
VENOUS THROMBOSIS:
10:30 - 11:00

Diagnosis and the role of thrombophilia testing

Participants in this presentation will gain an understanding of acquired and inherited causes of thrombophilia, the role of thrombophilia as risk factors for DVT, the role of thrombophilia in management of DVT and appropriate testing for thrombophilia in DVT.

Lai Heng Lee (Singapore)
11:00 - 11:30

Risk assessment and prevention of VTE

Participants in this session will learn to recognize the benefits and the importance of the prevention of venous thromboembolism; understand risk factors and risk assessment models to identify patient at risk for venous thromboembolism and gain an understanding of current guidelines for prevention of venous thromboembolism in surgical and medical patients.

Doyeun Oh (Korea)
11:30 - 12:00

Recent advances in VTE treatment

Following this lecture, the participants should be able to decide which patient with DVT or PE is suitable for pharmaco-mechanical thrombectomy; weigh the pros and cons of the different anticoagulants before initiating anticoagulation in the patient with DVT or PE; use the appropriate anticoagulant in special patient populations with DVT or PE, such as the patient who is obese, underwent bariatric surgery, is elderly, has cancer or with renal failure; discuss with the patient with DVT the benefits of compression stockings and advise a patient interested in taking testosterone on the thrombotic risk.

Stephan Moll (USA)
12:00 - 13:30 Lunch &sponsored symposium
VENOUS THROMBOSIS (SPECIAL POPULATIONS)
13:30 - 14:00

Cancer associated thrombosis

Participants in this session will gain an understanding of the pathophysiology and risk factors of VTE in cancer patients; learn to assess individual cancer patient’s risk of VTE and learn the current management of VTE in cancer patients. 

Pantep Angchaisuksiri (Thailand)
14:00 - 14:30 Antiphospholipid syndrome Christopher Ward (Australia)
14:30 - 15:00

Pediatric thrombosis

During this presentation, participants will learn the thrombophilic risk factors in children, gain an understanding of the development of hemostasis especially anticoagulation proteins during infancy and childhood and have the opportunity to join the network and registry of childhood thrombosis.

Nongnuch Sirachainan (Thailand)
15:00 - 15:30 Coffee break & networking
ANTITHROMBOTICS
15:30 - 16:00

DOACs in the real world

Participants in this presentation will gain an understanding of the real world indications and usage of DOACs, the real world evidence in safety and efficacy of DOACs, and the need to develop antithrombotic and bleeding protocols.

Lai Heng Lee (Singapore)
16:00 - 16:30

The risk of bleeding with DOACs in East Asia

By the end of this session, participants will be able to explain the concerns with the use of direct oral anticoagulants (DOACs) in East Asian patients with relatively small body weight; summarize the evidence regarding the use of DOACs as prophylaxis and treatment for thrombosis in East Asian patients and make clinical decisions about adjusting the doses of DOACs for patient management.

Satoshi Fujii (Japan)
16:30 - 17:00 Bleeding complications of anticoagulants Bundarika Suwanawiboon (Thailand)
17:00 - 17:30

Antiplatelet therapy

This presentation will elaborate on anti-platelet agents and anti-platelet therapy for various diseases, and the controversial issue of monitoring for anti-platelet therapy will also be covered.  The participants will be able to utilize their knowledge from the presentation in various clinical settings, which require anti-platelet therapy. 

Yukio Ozaki (Japan)
17:30 - 18:00

Case study/interactive presentation – patient with venous thrombosis

Participants will be invited to prepare case presentations for the audience and a discussion of the presentations will be moderated by Dr. Stephan Moll.

Moderator: Stephan Moll (USA)
18:00 - 18:15 Evaluation and farewell

Workshop Home
 | Registration | 
Accommodations



Questions? 
Email education@isth.org.

Membership Management Software Powered by YourMembership  ::  Legal